Infigratinib
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor
Trial Timeline
May 13, 2020 → Dec 30, 2023
NCT ID
NCT05019794About Infigratinib
Infigratinib is a phase 2 stage product being developed by LianBio for Gastric Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT05019794. Target conditions include Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06206278 | Phase 2 | Terminated |
| NCT05019794 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Gastric Cancer